Female Fertility Drugs Market: By Drug Type,, By Distribution Mode, By Route of Administration, By Distribution Channel and Geography
Female Fertility Drugs Market size was valued at US$ 3.48 billion in 2023 and is expected to reach US$ 5.35 billion in 2030, at a CAGR of 6.3% from 2024-2030. Female fertility drugs are the agents used to improve reproductive health in women and act to stimulate the follicle development of the ovary. Women's fertility drugs are extremely effective and the first treatment option to overcome infertility. Fertility drugs act by direct stimulation of ovaries or balancing the hormone levels. Infertility in women occurs due to hypothalamic dysfunction, excessive prolactin, pelvic inflammatory diseases, premature ovarian insufficiency, and polycystic ovary syndrome among others. The major symptom associated with infertility is an absence or irregular menstrual cycle. The female fertility drugs market is growing at a significant CAGR with several local and international players operating in infertility treatment.
The prevalence of infertility is increasing due to changes in lifestyles such as smoking and alcohol consumption. According to World Health Organization, approximately 60-80 Mn couples are suffering from infertility around the world. Moreover, acquisitions & mergers, collaborations, product approvals, and product launchings are the strategies followed by the companies for increasing their market revenue share in the female fertility drugs market. For instance, in March 2014, Ferring Pharmaceuticals received FDA approval for the combination of Menopur and Bravelle injection used in the treatment of infertility.
Study Period
2024-2030Base Year
2023CAGR
6.3%Largest Market
North AmericaFastest Growing Market
Europe
Increase in the female population, rise in prevalence of infertility condition due to change in lifestyle, government initiation for the infertility management, rise in disposable income are anticipated to fuel the women fertility drugs market over the forecast period. Moreover, increase in R&D activities for the development of new drugs to overcome the infertility, rise in the prevalence of obesity, and increase in the maternal age are expected to boost the women fertility drugs market. However, stringent regulatory policies for drug approvals, lack of awareness about women fertility drugs in underdeveloped countries, and alternative infertility treatments such as in vitro fertilization are expected to restrain the growth of women fertility drugs market over the forecast period.
Geographically, female fertility drugs market is segmented into the North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America driven by increase in the prevalence of female infertility rate due to obesity and lifestyle changes, increase in the R&D activities for the innovation of newer drugs, and rise in awareness about the fertility drugs among the key stakeholders in the region. Europe exhibiting significant growth rate owing to accessibility of the products, increase in the infertility rate in female due to hormonal imbalance, and lifestyle changes are the factors boost in the region. Moreover, Asia Pacific garnered significant share due to rise in female adult population, rise in female genital mutilation, and adoption of newer drugs in the region are the factors expected to upsurge the revenue of female fertility drugs market in the region.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 3.48 billion |
|
Market Size in 2030 |
US$ 5.35 billion |
|
Market CAGR |
6.3% |
|
By Drug Type |
|
|
By Route Administration |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
The Female fertility drugs market size was valued at US$ 3.48 billion in 2023.
The Female fertility drugs market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Female fertility drugs market key players are Sanofi S.A. (France), Merck KGaA (Germany), Novartis AG (Switzerland), Ferring B.V. (Switzerland), Berlex Laboratories Inc. (U.S.), Eli Lilly and Co. (U.S.), Serono Inc. (U.S.), Novogyne Pharmaceuticals (U.S.), Pfizer, Inc. (U.S.)
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
